Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176198 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT04176198: Recruiting Phase 1 study of Myelofibrosis, sponsored by Sumitomo Pharma America.
NCT04176198 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 240 participants, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04176198, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Primary Outcome
Number of participants with DLTs
Conditions Studied
Interventions
- DRUG Nusivertib
- DRUG Ruxolitinib
- DRUG Momelotinib
Study Locations (20)
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
- Hoag Family Cancer Institute - Newport Beach
Florida
- University of Florida Health Shands Cancer Hospital - Gainesville
- University of Miami - Miami
- Baptist Health - Miami Cancer Institute - Miami
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
Alabama
- University of Alabama - Birmingham
Arizona
- The University of Arizona Cancer Center - Tucson
Colorado
- Blood Cancer Center - Denver
Connecticut
- Yale School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
What NCT04176198 shows while recruiting
NCT04176198 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Nusivertib is the first listed.
NCT04176198 names 20 study sites across 15 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04176198 about?
NCT04176198 is a clinical study titled "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis". This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
What is the current status of trial NCT04176198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2019-12-16. Estimated completion is 2030-04-30.
What conditions does trial NCT04176198 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04176198?
The interventions under investigation include: Nusivertib (DRUG), Ruxolitinib (DRUG), Momelotinib (DRUG).
Who is sponsoring clinical trial NCT04176198?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04176198 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04176198's enrollment target sits among peer trials
240 10th of 61 higher than 52 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI